此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials

2022年4月11日 更新者：HIV Vaccine Trials Network

A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials

An observational study of long-term outcomes of HIV-1 infection in persons who become infected after enrollment in HIV-1 vaccine trials

研究概览

地位

完全的

条件

干预/治疗

详细说明

A descriptive and observational study of long-term outcomes of HIV-1 infection in persons who become HIV-1 infected after enrollment in HIV-1 vaccine trials

研究类型

观察性的

注册 (实际的)

209

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 南非
    • Gauteng
      • Johannesburg、Gauteng、南非、1862
        • Soweto HVTN CRS
    • Kwa Zulu Natal
      • Durban、Kwa Zulu Natal、南非、4013
        • eThekwini CRS
    • North West Province
      • Klerksdorp、North West Province、南非、2571
        • Aurum Institute Klerksdorp CRS
    • Western Cape
      • Cape Town、Western Cape、南非、7750
        • Emavundleni CRS
  • 多明尼加共和国
      • Santo Domingo、多明尼加共和国
        • Unidad de Vacunas IDCP-COIN-DIGECITSS CRS
  • 波多黎各
      • San Juan、波多黎各、00935
        • Maternal-Infant Studies Center (CEMI) CRS
  • 海地
      • Port-au-Prince、海地、HT-6110
        • Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
  • 秘鲁
    • Maynas
      • Iquitos、Maynas、秘鲁、1
        • ACSA CRS
  • 美国
    • Alabama
      • Birmingham、Alabama、美国、35294
        • Alabama Vaccine CRS
    • California
      • San Francisco、California、美国、94143
        • Bridge HIV CRS
    • Georgia
      • Decatur、Georgia、美国、30030
        • The Hope Clinic of the Emory Vaccine Center CRS
    • Illinois
      • Chicago、Illinois、美国、60612
        • UIC Project Wish CRS
    • Massachusetts
      • Boston、Massachusetts、美国、02115-6110
        • Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
      • Boston、Massachusetts、美国、02215-4302
        • Fenway Health Clinical Research Site CRS
    • New York
      • New York、New York、美国、10003
        • NY Blood Ctr./Union Square CRS
      • New York、New York、美国、10032-3732
        • Columbia P&S CRS
      • New York、New York、美国、10455
        • NY Blood Ctr./Bronx CRS
      • New York、New York、美国、14642
        • University of Rochester Vaccines to Prevent HIV Infection CRS
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • Penn Prevention CRS
    • Tennessee
      • Nashville、Tennessee、美国、37232-2582
        • Vanderbilt Vaccine (VV) CRS
    • Washington
      • Seattle、Washington、美国、98109-1024
        • Seattle Vaccine and Prevention CRS

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Both vaccine and placebo recipients in HVTN trials in which HIV infection constitutes an endpoint (eg, test-of-concept, phase 2 and 3) who become HIV-1 infected after enrollment in the parent study and who meet the inclusion criteria may be offered enrollment in the study.

描述

Inclusion Criteria:

  • Participants must meet the following criteria in order to be eligible for inclusion in the study:

    1. Confirmation of HIV-1 infection after enrollment in an HVTN vaccine trial in which HIV-1 infection constituted an endpoint, according to the diagnostic algorithm specified in the parent protocol.
    2. Ability and willingness to provide written informed consent to participate in the study.
    3. Ability and willingness to adhere to the on-study follow-up schedule.
    4. Ability and willingness to provide adequate information for locator purposes.
    5. Participants who are currently on ART or who previously received antiretrovirals as part of post-exposure prophylaxis, pre-exposure prophylaxis, or previous treatment regimen will be eligible for inclusion in this protocol. Their previous treatment history will be collected. If a participant has been on ART for more than 2 years, please consult with the protocol team leadership prior to enrollment.

    6. For participants initiating ART, agreement of participant and PHCP to initiate potent and durable ART regimens in accordance with local and international guidelines. Examples of potent and durable regimens are provided in Appendix H. Participants who initiate ART not consistent with regimens outlined in Appendix H may enroll with permission of the protocol chair or designee(s).

      Exclusion Criteria:

  • Persons who meet the following criteria will be excluded from the study:

    1. Any medical, psychiatric, alcohol/drug dependency or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence or a participant's ability to give informed consent.
    2. Participants who meet these additional criteria will be excluded from the study:
  • Participants undergoing acute therapy for serious medical illnesses (in the opinion of the site investigator) within 14 days prior to initiation of ART.
  • Participants with chronic, acute, or recurrent infections that are serious (in the opinion of the site investigator).
  • Participants who must continue with chronic (maintenance) therapy (e.g., tuberculosis [TB], pneumocystis pneumonia [PCP]), must have completed at least 14 days of therapy and be clinically stable prior to initiation of ART.
  • Oral and vaginal candidiasis, mucocutaneous herpes simplex, and other minor illnesses, as defined by the site investigator, present no restriction to eligibility.
  • Participants undergoing radiation therapy, systemic chemotherapy, or receiving an immunomodulator within 45 days prior to initiation of ART. (A tapering course of corticosteroids as acute therapy for PCP or other conditions is an exception.)

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 观测模型：队列
  • 时间观点：预期

队列和干预

团体/队列
干预/治疗
Participants infected with HIV-1
Persons who become HIV-1 infected after enrollment in HIV-1 vaccine trials
其他：观察

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Measure plasma HIV-1 RNA levels and CD4+ T cell counts longitudinally
大体时间：8 years
Blood samples will be processed for PBMCs and then cryopreserved. These specimens will be stimulated with synthetic HIV-1 peptide pools. This process will allow ex vivo HIV-specific T-cell responses to be assessed by IFN-γ ELISpot and/or flow cytometry.
8 years
Measure time to initiation of ART
大体时间：8 years
Blood samples will be processed for PBMCs and then cryopreserved. These specimens will be stimulated with synthetic HIV-1 peptide pools. This process will allow ex vivo HIV-specific T-cell responses to be assessed by IFN-γ ELISpot and/or flow cytometry.
8 years
Measure time to HIV-1 related clinical events
大体时间：8 years

Blood samples will be processed for PBMCs and then cryopreserved. These specimens will be stimulated with synthetic HIV-1 peptide pools. This process will allow ex vivo HIV-specific T-cell responses to be assessed by IFN-γ ELISpot and/or flow cytometry.

Responses from ELISpot assays will be reported as the number of spot-forming cells Blood samples will be processed for PBMCs and then cryopreserved. These specimens will be stimulated with synthetic HIV-1 peptide pools. This process will allow ex vivo HIV-specific T-cell responses to be assessed by IFN-γ ELISpot and/or flow cytometry.
8 years
Proportion of individuals with plasma HIV-1 RNA level <50 copies/mL at 24 weeks after initiation of ART
大体时间：8 years

Blood samples will be processed for PBMCs and then cryopreserved. These specimens will be stimulated with synthetic HIV-1 peptide pools. This process will allow ex vivo HIV-specific T-cell responses to be assessed by IFN-γ ELISpot and/or flow cytometry.

Responses from ELISpot assays will be reported as the number of spot-forming cells Blood samples will be processed for PBMCs and then cryopreserved. These specimens will be stimulated with synthetic HIV-1 peptide pools. This process will allow ex vivo HIV-specific T-cell responses to be assessed by IFN-γ ELISpot and/or flow cytometry.
8 years

次要结果测量

结果测量
措施说明
大体时间
Time from initiation of ART to treatment failure due to virologic, immunologic, and clinical reasons
大体时间：8 years
Blood samples will be processed for PBMCs and then cryopreserved. These specimens will be stimulated with synthetic HIV-1 peptide pools. This process will allow ex vivo HIV-specific T-cell responses to be assessed by IFN-γ ELISpot and/or flow cytometry.
8 years
Occurrence of HIV/AIDS associated events, including death
大体时间：8 years
Blood samples will be processed for PBMCs and then cryopreserved. These specimens will be stimulated with synthetic HIV-1 peptide pools. This process will allow ex vivo HIV-specific T-cell responses to be assessed by IFN-γ ELISpot and/or flow cytometry.
8 years
Proportion of subjects with HIV-1 RNA level <50 copies/mL post-initiation of ART; log change in plasma HIV-1 RNA levels and change in CD4+ T cell levels between baseline (at initiation of ART) and post-initiation of ART
大体时间：24, 48, 96, and 144 weeks
Blood samples will be processed for PBMCs and then cryopreserved. These specimens will be stimulated with synthetic HIV-1 peptide pools. This process will allow ex vivo HIV-specific T-cell responses to be assessed by IFN-γ ELISpot and/or flow cytometry.
24, 48, 96, and 144 weeks
Adherence information collected at 24, 48, 96, and 144 weeks following initiation of ART
大体时间：24, 48, 96, and 144 weeks
Blood samples will be processed for PBMCs and then cryopreserved. These specimens will be stimulated with synthetic HIV-1 peptide pools. This process will allow ex vivo HIV-specific T-cell responses to be assessed by IFN-γ ELISpot and/or flow cytometry.
24, 48, 96, and 144 weeks
Side effects collected at 24, 48, 96, and 144 weeks following initiation of ART
大体时间：24, 48, 96, and 144 weeks
Blood samples will be processed for PBMCs and then cryopreserved. These specimens will be stimulated with synthetic HIV-1 peptide pools. This process will allow ex vivo HIV-specific T-cell responses to be assessed by IFN-γ ELISpot and/or flow cytometry.
24, 48, 96, and 144 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

HIV Vaccine Trials Network

调查人员

  • 学习椅：Magdalena Sobieszcyk、Columbia University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2008年7月11日

初级完成 (实际的)

2015年7月11日

研究完成 (实际的)

2016年7月1日

研究注册日期

首次提交

2017年11月7日

首先提交符合 QC 标准的

2017年11月7日

首次发布 (实际的)

2017年11月9日

研究记录更新

最后更新发布 (实际的)

2022年4月18日

上次提交的符合 QC 标准的更新

2022年4月11日

最后验证

2022年4月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • HVTN 802

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅